Acylated derivative of homoharringtonine, preparation method therefor, and application thereof

1. An acylated homoharringtonine compound of formula (I) or formula (II):

or a pharmaceutically acceptable salt thereof;

wherein

R 1 and R 2 are independently selected from H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, C 4 -C 20 conjugated alkenyl, C 3 -C 7 cycloalkyl or cycloalkenyl, aryl, heterocyclyl, heteroaryl, and amino acid side chain residues, which, except for H, are optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C 1 -C 6 alkyl amino, nitro, cyano, hydroxyl, C 1 -C 6 alkoxy, thiol and C 1 -C 6 alkylthio;

said C 3 -C 7 cycloalkyl or cycloalkenyl, aryl, heterocyclyl or heteroaryl are further optionally substituted with C 1 -C 6 alkyl; and

said C 1 -C 20 alkyl, C 2 -C 20 alkenyl or C 4 -C 20 conjugated alkenyl are further optionally substituted with aryl or heteroaryl.

2. The acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 1 and R 2 are independently selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 4 -C 8 conjugated alkenyl, C 3 -C 7 cycloalkyl or cycloalkenyl, aryl, heterocyclyl, heteroaryl and amino acid side chain residues, which, except for H, are optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C 1 -C 4 alkyl amino, nitro, cyano, hydroxyl, C 1 -C 4 alkoxy, thiol and C 1 -C 4 alkylthio;

said C 3 -C 7 cycloalkyl or cycloalkenyl, aryl, heterocyclyl or heteroaryl are further optionally substituted with C 1 -C 4 alkyl; and

said C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 4 -C 8 conjugated alkenyl are further optionally substituted with aryl or heteroaryl.

3. The acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

R 1 and R 2 are independently selected from C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 7 cycloalkyl, aryl and heteroaryl, which are optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C 1 -C 4 alkylamino, nitro, cyano, hydroxyl, C 1 -C 4 alkoxy, thiol and C 1 -C 4 alkylthio;

said C 3 -C 7 cycloalkyl, aryl and heteroaryl are further optionally substituted with C 1 -C 4 alkyl; and

said C 1 -C 6 alkyl or C 2 -C 6 alkenyl are further optionally substituted with aryl or heteroaryl.

4. The acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently selected from the group consisting of a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with aryl or heteroaryl, a C 2 -C 6 alkenyl, a C 2 -C 6 alkenyl substituted with aryl or heteroaryl, a C 3 -C 7 cycloalkyl, an aryl, an aryl substituted with C 1 -C 4 alkyl, a heteroaryl and a heteroaryl substituted with C 1 -C 4 alkyl, each of which are optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C 1 -C 4 alkyl amino, nitro, cyano, hydroxyl, C 1 -C 4 alkoxy, thiol and C 1 -C 4 alkylthio.

5. The acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently selected from the group consisting of a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with aryl or heteroaryl, a C 2 -C 6 alkenyl, a C 2 -C 6 alkenyl substituted with aryl or heteroaryl, a C 3 -C 7 cycloalkyl, aryl, an aryl substituted with C 1 -C 4 alkyl, a heteroaryl and a heteroaryl substituted with C 1 -C 4 alkyl, each of which is optionally substituted with one or more halogen atoms.

6. The acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein

said aryl is phenyl;

said heteroaryl is furanyl, thiophenyl, pyridinyl, oxazolyl or isoxazolyl;

said C 3 -C 7 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and

wherein each aryl, heteroaryl or C 3 -C 7 cycloalkyl is optionally substituted with C 1 -C 4 alkyl or halogen.

7. The acylated homoharringtonine compound of claim 6 , or a pharmaceutically acceptable salt thereof, wherein

said aryl is phenyl;

said heteroaryl is furanyl, thiophenyl, pyridinyl, oxazolyl or isoxazolyl;

said C 3 -C 7 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and

wherein each aryl, heteroaryl, or C 3 -C 7 cycloalkyl is optionally substituted with methyl, chlorine or bromine.

8. The acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

9. The acylated homoharringtonine compound of claim 8 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of a C 1 -C 6 alkyl, a C 1 -C 6 alkyl substituted with aryl or heteroaryl, a C 3 -C 7 cycloalkyl, an aryl, an aryl substituted with C 1 -C 4 alkyl, a heteroaryl and a heteroaryl substituted with C 1 -C 4 alkyl, each of which is optionally substituted with one or more halogen atoms.

10. The acylated homoharringtonine compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein

said aryl is phenyl;

said heteroaryl is furanyl, pyridinyl or thiazolyl;

said cycloalkyl is cyclopentyl; and

wherein each aryl, heteroaryl or cycloalkyl is optionally substituted with one or more halogen atoms.

11. The acylated homoharringtonine compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein R 1 is selected from the group consisting of methyl, furanyl, pyridinyl optionally substituted with halogen, thiazolyl optionally substituted with methyl, phenyl, and cyclopentyl.

12. The acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is a compound selected from the group consisting of

13. A process for preparing the compound of formula (I) according to claim 1 , comprising:

1) subjecting an optionally activated homoharringtonine and an organic acid R 1 CO 2 H to condensation esterification;

2) subjecting homoharringtonine and an organic acyl chloride R 1 COCl or an organic anhydride (R 1 CO) 2 O to condensation esterification; or

3) reacting an activated organic acid R 1 CO 2 H with homoharringtonine;

to obtain the compound of formula (I), wherein R 1 is as defined in claim 1 .

14. A process for preparing the compound of formula (II) according to claim 1 , comprising:

1) subjecting an optionally activated homoharringtonine and an organic acid R 1 CO 2 H to condensation esterification (wherein R 1 ═R 2 ) or subjecting an optionally activated compound of formula (I) and an organic acid R 2 CO 2 H to condensation esterification;

2) subjecting homoharringtonine and an organic acyl chloride R 1 COCl or an organic anhydride (R 1 CO) 2 O to condensation esterification (wherein R 1 ═R 2 ), or subjecting the compound of formula (I) and an organic acyl chloride R 2 COCl or an organic anhydride (R 2 CO) 2 O to condensation esterification; or

3) reacting an activated organic acid R 1 CO 2 H with homoharringtonine (wherein R 1 ═R 2 ) or reacting an activated organic acid R 2 CO 2 H with a compound of formula (I);

to obtain the compound of formula (II), wherein R 1 is as defined in claim 1 .

15. A pharmaceutical composition, comprising the acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

16. A method for treating a subject suffering from tumor, comprising administering to the subject in need thereof an effective amount of the acylated homoharringtonine compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the tumor is selected from the group consisting of leukemia, multiple myeloma, lymphoma, liver cancer, gastric cancer, breast cancer, cholangiocellular carcinoma, pancreatic cancer, lung cancer, colorectal cancer, osteosarcoma, human cervical cancer, glioma, nasopharyngeal carcinoma, laryngeal carcinoma, esophageal cancer, middle ear tumor, melanoma, and prostate cancer.